News

BioVie Announces Clinical Data Showing Epigenetic Basis for How Bezisterim May Modulate Inflammation and the Biological Aging Process at the 11th Aging Research and Drug Discovery Meeting

Bezisterim appears to possess broad homeostatic properties relevant to inflammation and human disorders related to aging Patients treated with bezisterim…

1 year ago

CervoMed to Participate in Upcoming Investor Conferences

BOSTON, Aug. 27, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for…

1 year ago

RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright’s 26th Annual Global Investment Conference on September 9, 2024 in New York

LOS ALTOS, Calif., Aug. 27, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical…

1 year ago

Autonomix Medical, Inc. to Present at H.C. Wainwright 26th Annual Global Investment Conference

THE WOODLANDS, TX, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical…

1 year ago

Femasys Hosts Congresswoman Lucy McBath at Georgia Headquarters

The Congresswoman representing Georgia’s 7th district in the U.S. House of Representatives toured Femasys’ facilities to gain a better understanding…

1 year ago

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Issued for PfGARP Malaria Antibodies Central to Company’s Malaria Treatment and Prevention Platforms

Figure: 1 Elements of Ocean Biomedical Multi-pronged Malaria Program Testing Result Figure: 2 Dr. Jonathan Kurtis conducting research near Kisumu,…

1 year ago

SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference

JERSEY CITY, N.J., Aug. 27, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to…

1 year ago

Korro to Participate in Upcoming September Investor and Scientific Conferences

CAMBRIDGE, Mass., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a biopharmaceutical company focused on developing…

1 year ago

Soleno Therapeutics Announces U.S. FDA Acceptance for Filing and Priority Review of NDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome

PDUFA target action date set for December 27, 2024 FDA currently plans to hold an Advisory Committee meeting REDWOOD CITY,…

1 year ago

Spectral AI Completes Burn Center Enrollment for U.S. Burn Pivotal Study

Milestone Achievement Advances Commercialization Timeline for DeepView™ System for Burn IndicationDALLAS, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc.…

1 year ago